[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stenosis-artery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stenosis-artery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100574321","phase-4-the-effect-and-safety-of-combined-anti-platelet-treatment-in-acute-ischemic-stroke-due-to-large-artery-atherosclerosis-100574321",false,"NCT06757764","The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial","CHANGE","Inclusion Criteria:\n\n1. Age of 20 years or older\n2. Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography.\n3. Informed consent obtained within 72h from stroke onset\n4. Acquisition of written informed consent prior to study entry\n\nExclusion Criteria:\n\n1. Large infarction unable to start antiplatelet treatment\n2. Combined with acute intracranial haemorrhage\n3. With initial haemorrhagic transformation\n4. Previous mRS higher than 2\n5. Indicated for anticoagulation\n6. Contraindication for aspirin, clopidogrel or cilostazol\n7. Requirement of long term NSAID\n8. Pre-planned for surgery\n9. Unable to withdraw consent\n10. Unavailable to participate based on judgement of the investigator\n11. Participants of reproductive potential (PORP)\u002F Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception.","ALL","20 Years",{"count":20,"type":21},2340,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.",[27,28],"Cerebral Infarction","Stenosis Artery","RECRUITING","2026-03-25",{"date":32,"type":33},"2026-03-27","ACTUAL",{"date":35,"type":33},"2025-07-10",{"date":37,"type":21},"2028-03-31",{"name":39,"class":40},"Asan Medical Center","OTHER",24,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100492495","a-registry-study-of-intracranial-atherosclerotic-stenosis-treatment-by-intracranial-drug-eluting-stenting-in-china-100492495","NCT05692882","A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China","To Evaluate the Safety and Efficacy of the NOVA Intracranial Drug-eluting Stent System in \"real World\" Patients with Intracranial Atherosclerotic Stenosis: a Prospective, Multicenter, Post-marketing Registry Clinical Study (NOVA II)","Inclusion Criteria:\n\n1. Males or females between 18 and 80 years of age;\n2. Symptomatic intracranial arteriosclerosis stenosis with reference diameter 2.25-4.00mm;\n3. intracranial artery stenosis ( ≥70%) conformed by digital subtraction angiography (DSA);\n4. Those who voluntarily participate in the study and sign informed consent form.\n\nExclusion Criteria:\n\n1. Those who have surgery within previous 30 days or plan to perform major surgery in the next 90 days (surgery grade 3 and above);\n2. Subjects of acute hemorrhagic stroke within 3 months;\n3. The baseline mRS of disabling stroke is more than 3;\n4. The target vessel is severely calcified and closely related to stenosis;\n5. Non-atherosclerotic diseases (e.g. arterial dissection, Moya Moya disease, vascular inflammatory lesions caused by infection, autoimmune diseases, post-irradiation, postpartum status; developmental or genetic abnormalities such as fibromuscular dysplasia, sickle cell anemia, suspected vasospasm);\n6. It is suspected that the ischemic event is due to embolism or arterial embolism from the extracranial segment (including ipsilateral chest or neck vascular occlusive disease) or potential cardiogenic embolism (e.g. atrial fibrillation, mitral stenosis, patent foramen ovale, left ventricular thrombus, myocardial infarction within 6 weeks, etc.);\n7. Target artery's supplying artery stenosis \\> 50%. For example, patient with middle cerebral artery (MCA) severe stenosis (target artery) and the ipsilateral internal carotid artery (ICA) stenosis \\> 50% should be excluded; patient with basilar artery (BA) severe stenosis (target artery) and the dominant vertical artery (VA) stenosis \\> 50% should be excluded;\n8. There are intracranial tumors, or intracranial arteriovenous malformations;\n9. Those who are allergic to heparin, aspirin, clopidogrel, contrast agents, anesthetics, and stent components;\n10. Pregnant and lactating women\n11. Those who are unable to complete follow-up because of mental illness, cognitive or emotional disorders;\n12. Inapplicable for this study at the investigators' viewpoints.","18 Years","85 Years",{"count":52,"type":21},1000,[54],"NA","The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in \"real world\" patients with intracranial atherosclerotic stenosis.",[57,28,58,59],"Intracranial Arteriosclerosis","Drug-Eluting Stents","Intracranial Artery Stenosis",[61,62,63],"endovascular therapy","intracranial drug-eluting stent","symptomatic intracranial artery stenosis (sICAS)","2025-03-26",{"date":66,"type":33},"2025-04-01",{"date":68,"type":33},"2023-11-16",{"date":70,"type":21},"2029-12-30",{"name":72,"class":73},"Sino Medical Sciences Technology Inc.","INDUSTRY",5]